← Back to Calendar
Indication
Neurology — Los Angeles, CA
Key Notes
AAN Annual Meeting 2026: April 5–9, Los Angeles Convention Center. COMPLETED. Key presentations: Grace Therapeutics (GRCE) abstract on STRIVE-ON Phase 3 GTx-104 results accepted (PDUFA April 23, 2026); Praxis ulixacaltamide and relutrigine PDUFA prep updates; Biogen/Eisai Leqembi subcutaneous safety data; CNS precision medicine programs. Movement disorder and epilepsy data presented ahead of upcoming PDUFA dates.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.